Pluristem Announced it Received Approval for Grant from the Israel Innovation Authority to Develop its Next-Generation CRISPR PLX Platform
Pluristem Therapeutics Inc. (NASDAQ: PSTI) (TASE:PSTI), a leading biotechnology company, today announced that it has received approval for an additional grant from the Israel Innovation Authority (IIA) to support research based on its cutting-edge PLX platform.